RGCC OncoTrace: Real-Time Radar for Monitoring Tumour Dynamics
RGCC OncoTrace is one of the most advanced circulating tumour cell (CTC) detection and monitoring technologies available internationally. With a single blood draw, it can capture cancer cells that have “escaped” the tumour and are circulating in the blood, providing key information on quantity, phenotype, and activity. This allows physicians to detect changes before tumour markers rise or imaging shows any alteration.
Why RGCC OncoTrace is particularly suitable for patients requiring close monitoring
- Detects changes earlier and with greater sensitivity than traditional tumour markers (CEA, CA19-9, CA125, etc.)
- More frequent, lower radiation, and more cost-effective than imaging scans (CT, PET-CT)
- Able to identify minimal residual disease (MRD) and early recurrence signals
- Provides CTC count trend charts to help physicians assess whether treatment is truly suppressing the tumour
- Simultaneously analyses CTC phenotype to assist in predicting metastasis risk and prognosis
Who is especially suited for regular use of RGCC OncoTrace
- Solid tumour patients at intermediate to high risk of recurrence after surgery
- Patients who have completed adjuvant therapy and entered the follow-up phase
- Those with fluctuating tumour markers but no clear changes on imaging
- Individuals with a history of distant metastasis hoping for earlier detection of recurrence
- Patients seeking a more precise monitoring tool alongside conventional treatment
Practical application (determined by the physician based on individual circumstances)
- Blood test every 3–6 months (synchronised with routine follow-up)
- Each report includes CTC count, activity, phenotype analysis, and trend chart
- The physician integrates imaging, markers, and clinical symptoms to provide the clearest next steps
Summary
RGCC OncoTrace does not replace conventional follow-up —
it adds an earlier, more precise layer of protection.
It transforms long-term monitoring from “anxious waiting every few months”
into “knowing at any time that your body is moving in the right direction”.
If you are currently in post-surgical follow-up, have completed adjuvant therapy, or feel uneasy about recurrence risk, please feel welcome to contact us at any time.
Our integrative oncology team will review your treatment history and risk profile, and your specialist physician will assess whether adding RGCC OncoTrace monitoring is appropriate, helping every step feel clearer and more reassuring.
You deserve to experience each day of follow-up with greater peace of mind and confidence.
Disclaimer：
The information provided in this article is for educational and informational purposes only. It is not intended to diagnose, treat, cure, or prevent any disease, nor should it replace professional medical advice. Readers are encouraged to consult with a qualified healthcare provider or integrative oncology specialist before making any changes to their diet, treatment plan, or lifestyle based on the content herein. Therapies and tests mentioned, including immune or integrative treatments, should always be…
All product names, test references, and therapy mentions are for informational context only and do not constitute endorsement. Results and experiences may vary among individuals.